Truist Financial Increases Lantheus (NASDAQ:LNTH) Price Target to $141.00

Lantheus (NASDAQ:LNTH) had its price objective increased by research analysts at Truist Financial from $96.00 to $141.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price points to a potential upside of 14.24% from the company’s current price.

A number of other equities analysts have also recently commented on the stock. SVB Leerink lifted their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday. JMP Securities upped their target price on shares of Lantheus from $100.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. B. Riley boosted their price target on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. Finally, Mizuho increased their price objective on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and a consensus target price of $113.86.

Lantheus Price Performance

Shares of LNTH opened at $123.42 on Thursday. The firm has a fifty day moving average price of $81.97 and a 200 day moving average price of $67.79. The stock has a market cap of $8.55 billion, a PE ratio of 18.84 and a beta of 0.51. Lantheus has a 1-year low of $50.20 and a 1-year high of $124.90. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.11. The firm had revenue of $369.98 million during the quarter, compared to analysts’ expectations of $349.46 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. As a group, sell-side analysts anticipate that Lantheus will post 6.46 EPS for the current year.

Insider Activity

In related news, Director Heinz Christoph Maeusli sold 18,373 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the transaction, the director now owns 23,340 shares of the company’s stock, valued at $1,848,294.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Heinz Christoph Maeusli sold 18,373 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the sale, the director now owns 23,340 shares of the company’s stock, valued at $1,848,294.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $76.89, for a total transaction of $26,219.49. Following the transaction, the chief accounting officer now owns 62,898 shares in the company, valued at $4,836,227.22. The disclosure for this sale can be found here. Insiders sold 44,799 shares of company stock valued at $3,748,151 in the last three months. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of Lantheus

Institutional investors have recently bought and sold shares of the company. Farallon Capital Management LLC boosted its position in shares of Lantheus by 595.3% in the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after buying an additional 1,269,900 shares in the last quarter. Norges Bank acquired a new stake in shares of Lantheus in the fourth quarter valued at approximately $29,956,000. Reinhart Partners LLC. increased its stake in shares of Lantheus by 50.4% during the 4th quarter. Reinhart Partners LLC. now owns 1,356,273 shares of the medical equipment provider’s stock worth $84,089,000 after purchasing an additional 454,753 shares in the last quarter. Swedbank AB acquired a new position in shares of Lantheus during the 1st quarter worth approximately $26,346,000. Finally, Nomura Holdings Inc. lifted its stake in Lantheus by 105.3% in the 4th quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider’s stock valued at $1,282,000 after buying an additional 407,507 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.